Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma
ByDaniel V. T. Catenacci, MD,Yoon-Koo Kang, MD, PhD,Hope E. Uronis, MD, MHS,Keun-Wook Lee, MD, PhD,Matthew C. H. Ng, MD,Peter C. Enzinger, MD,Se Hoon Park, MD, PhD,Philip J. Gold, MD,Jill Lacy, MD,Howard S. Hochster, MD,Sang Cheul Oh, MD, PhD,Yeul Hong Kim, MD, PhD,Kristen A. Marrone, MD,Ronan J. Kelly, MD,Rosalyn A. Juergens, MD,Jong Gwang Kim, MD, PhD,Thierry Alcindor, MD, MSc,Sun Jin Sym, MD, PhD,Eun-Kee Song, MD, PhD,Cheng Ean Chee, MD,Yee Chao, MD, PhD,Sunnie Kim, MD,Do-Youn Oh, MD, PhD,Jennifer Yen, PhD,Justin I. Odegaard, MD, PhD,Errin Lagow, PhD,Daner Li, MS,Jichao Sun, PhD,Patrick Kaminker, PhD,Paul A. Moore, PhD,Minori Koshiji Rosales, MD, PhD,Haeseong Park, MD, MPH
Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
